23 Investor presentation Full year 2021 Novo Nordisk has leading positio haemophilia DKK billion 800 Diabetes care #1 50% DKK billion 16 Obesity 600 400 200 0 Nov 2016 40% 30% 20% CAGR 1 value: 10.1% 10% Market value Nov 0% 2021 NN value market share (RHS) Global market position 12 8 4 0 Nov 2019 CAGR 2 va Market v NN value Global m 1 CAGR for 5-year period; 2 CAGR for 2-year period; 3 CAGR for 5-year period; Note: Annual sales figures for haemophilia A, B and byp Source: Company reports for haemophilia market- FY21 numbers ready by Q1’22; IQVIA MAT, Nov 2021; Note: Diabetes and Obesit NN: Novo Nordisk
Download PDF file